nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Dactinomycin—germ cell cancer	0.0857	0.141	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—germ cell cancer	0.0691	0.114	CbGbCtD
Dabrafenib—CYP2C8—Ifosfamide—germ cell cancer	0.0539	0.0887	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—germ cell cancer	0.0492	0.081	CbGbCtD
Dabrafenib—ABCG2—Etoposide—germ cell cancer	0.0484	0.0795	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—germ cell cancer	0.0402	0.0662	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—germ cell cancer	0.0371	0.0611	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—germ cell cancer	0.032	0.0526	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—germ cell cancer	0.0309	0.0508	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—germ cell cancer	0.0259	0.0425	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—germ cell cancer	0.0258	0.0424	CbGbCtD
Dabrafenib—CYP3A4—Ifosfamide—germ cell cancer	0.0219	0.036	CbGbCtD
Dabrafenib—ABCB1—Vinblastine—germ cell cancer	0.0194	0.0318	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—germ cell cancer	0.0178	0.0292	CbGbCtD
Dabrafenib—ABCB1—Etoposide—germ cell cancer	0.0174	0.0287	CbGbCtD
Dabrafenib—CYP3A4—Vinblastine—germ cell cancer	0.0116	0.0191	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—germ cell cancer	0.0115	0.0189	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—germ cell cancer	0.0105	0.0172	CbGbCtD
Dabrafenib—SLC22A8—choroid plexus—germ cell cancer	0.00921	0.0784	CbGeAlD
Dabrafenib—SLC22A8—optic choroid—germ cell cancer	0.00353	0.0301	CbGeAlD
Dabrafenib—NEK11—uterus—germ cell cancer	0.00314	0.0267	CbGeAlD
Dabrafenib—NEK11—medulla oblongata—germ cell cancer	0.00297	0.0253	CbGeAlD
Dabrafenib—NEK11—adrenal gland—germ cell cancer	0.00275	0.0234	CbGeAlD
Dabrafenib—LIMK1—telencephalon—germ cell cancer	0.00271	0.023	CbGeAlD
Dabrafenib—LIMK1—decidua—germ cell cancer	0.00257	0.0218	CbGeAlD
Dabrafenib—NEK11—female gonad—germ cell cancer	0.00257	0.0218	CbGeAlD
Dabrafenib—SLC22A8—urine—germ cell cancer	0.00246	0.021	CbGeAlD
Dabrafenib—NEK11—testis—germ cell cancer	0.00228	0.0194	CbGeAlD
Dabrafenib—NEK11—cerebellum—germ cell cancer	0.0021	0.0179	CbGeAlD
Dabrafenib—LIMK1—adrenal gland—germ cell cancer	0.00197	0.0168	CbGeAlD
Dabrafenib—LIMK1—midbrain—germ cell cancer	0.00194	0.0166	CbGeAlD
Dabrafenib—SIK1—trigeminal ganglion—germ cell cancer	0.00178	0.0152	CbGeAlD
Dabrafenib—NEK11—brain—germ cell cancer	0.00171	0.0145	CbGeAlD
Dabrafenib—NEK11—lymph node—germ cell cancer	0.00165	0.014	CbGeAlD
Dabrafenib—RAF1—neck—germ cell cancer	0.00164	0.014	CbGeAlD
Dabrafenib—LIMK1—testis—germ cell cancer	0.00163	0.0139	CbGeAlD
Dabrafenib—LIMK1—cerebellum—germ cell cancer	0.0015	0.0128	CbGeAlD
Dabrafenib—RAF1—trigeminal ganglion—germ cell cancer	0.00142	0.0121	CbGeAlD
Dabrafenib—SIK1—telencephalon—germ cell cancer	0.0014	0.0119	CbGeAlD
Dabrafenib—BRAF—uterus—germ cell cancer	0.00139	0.0118	CbGeAlD
Dabrafenib—RAF1—embryo—germ cell cancer	0.00137	0.0117	CbGeAlD
Dabrafenib—BRAF—pituitary gland—germ cell cancer	0.00136	0.0116	CbGeAlD
Dabrafenib—SIK1—skin of body—germ cell cancer	0.00134	0.0114	CbGeAlD
Dabrafenib—SIK1—decidua—germ cell cancer	0.00133	0.0113	CbGeAlD
Dabrafenib—RAF1—brainstem—germ cell cancer	0.00126	0.0107	CbGeAlD
Dabrafenib—RAF1—eye—germ cell cancer	0.00122	0.0104	CbGeAlD
Dabrafenib—LIMK1—brain—germ cell cancer	0.00122	0.0104	CbGeAlD
Dabrafenib—CYP3A4—urine—germ cell cancer	0.00122	0.0104	CbGeAlD
Dabrafenib—BRAF—adrenal gland—germ cell cancer	0.00122	0.0104	CbGeAlD
Dabrafenib—BRAF—midbrain—germ cell cancer	0.0012	0.0102	CbGeAlD
Dabrafenib—LIMK1—lymph node—germ cell cancer	0.00118	0.01	CbGeAlD
Dabrafenib—BRAF—bone marrow—germ cell cancer	0.00118	0.01	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—germ cell cancer	0.00117	0.00999	CbGeAlD
Dabrafenib—SIK1—gonad—germ cell cancer	0.00117	0.00995	CbGeAlD
Dabrafenib—SIK1—uterus—germ cell cancer	0.00116	0.00988	CbGeAlD
Dabrafenib—SIK1—pituitary gland—germ cell cancer	0.00114	0.0097	CbGeAlD
Dabrafenib—BRAF—female gonad—germ cell cancer	0.00113	0.00966	CbGeAlD
Dabrafenib—RAF1—telencephalon—germ cell cancer	0.00111	0.00949	CbGeAlD
Dabrafenib—SIK1—medulla oblongata—germ cell cancer	0.0011	0.00937	CbGeAlD
Dabrafenib—RAF1—skin of body—germ cell cancer	0.00106	0.00905	CbGeAlD
Dabrafenib—RAF1—decidua—germ cell cancer	0.00106	0.00899	CbGeAlD
Dabrafenib—SIK1—adrenal gland—germ cell cancer	0.00102	0.00867	CbGeAlD
Dabrafenib—BRAF—testis—germ cell cancer	0.00101	0.00857	CbGeAlD
Dabrafenib—SIK1—bone marrow—germ cell cancer	0.000985	0.00839	CbGeAlD
Dabrafenib—SIK1—spinal cord—germ cell cancer	0.000981	0.00835	CbGeAlD
Dabrafenib—SIK1—female gonad—germ cell cancer	0.000949	0.00808	CbGeAlD
Dabrafenib—RAF1—gonad—germ cell cancer	0.00093	0.00792	CbGeAlD
Dabrafenib—BRAF—cerebellum—germ cell cancer	0.000929	0.00791	CbGeAlD
Dabrafenib—RAF1—uterus—germ cell cancer	0.000924	0.00787	CbGeAlD
Dabrafenib—SLCO1B3—endocrine gland—germ cell cancer	0.000909	0.00774	CbGeAlD
Dabrafenib—RAF1—pituitary gland—germ cell cancer	0.000907	0.00772	CbGeAlD
Dabrafenib—SIK1—endocrine gland—germ cell cancer	0.000883	0.00752	CbGeAlD
Dabrafenib—RAF1—medulla oblongata—germ cell cancer	0.000875	0.00745	CbGeAlD
Dabrafenib—SIK1—head—germ cell cancer	0.000872	0.00742	CbGeAlD
Dabrafenib—SIK1—testis—germ cell cancer	0.000842	0.00717	CbGeAlD
Dabrafenib—SLC22A8—trigeminal ganglion—germ cell cancer	0.000825	0.00702	CbGeAlD
Dabrafenib—RAF1—adrenal gland—germ cell cancer	0.00081	0.0069	CbGeAlD
Dabrafenib—RAF1—midbrain—germ cell cancer	0.0008	0.00681	CbGeAlD
Dabrafenib—RAF1—bone marrow—germ cell cancer	0.000784	0.00668	CbGeAlD
Dabrafenib—RAF1—spinal cord—germ cell cancer	0.000781	0.00665	CbGeAlD
Dabrafenib—SIK1—cerebellum—germ cell cancer	0.000778	0.00662	CbGeAlD
Dabrafenib—RAF1—female gonad—germ cell cancer	0.000756	0.00643	CbGeAlD
Dabrafenib—BRAF—brain—germ cell cancer	0.000755	0.00643	CbGeAlD
Dabrafenib—BRAF—lymph node—germ cell cancer	0.000729	0.00621	CbGeAlD
Dabrafenib—SLC22A8—eye—germ cell cancer	0.000711	0.00605	CbGeAlD
Dabrafenib—RAF1—endocrine gland—germ cell cancer	0.000703	0.00598	CbGeAlD
Dabrafenib—RAF1—head—germ cell cancer	0.000694	0.00591	CbGeAlD
Dabrafenib—RAF1—testis—germ cell cancer	0.00067	0.00571	CbGeAlD
Dabrafenib—SIK1—brain—germ cell cancer	0.000632	0.00538	CbGeAlD
Dabrafenib—RAF1—cerebellum—germ cell cancer	0.000619	0.00527	CbGeAlD
Dabrafenib—SIK1—lymph node—germ cell cancer	0.00061	0.0052	CbGeAlD
Dabrafenib—ABCG2—trigeminal ganglion—germ cell cancer	0.000587	0.005	CbGeAlD
Dabrafenib—Aspartate aminotransferase increased—Cisplatin—germ cell cancer	0.000536	0.00314	CcSEcCtD
Dabrafenib—Anaemia—Vinblastine—germ cell cancer	0.000532	0.00312	CcSEcCtD
Dabrafenib—Nasopharyngitis—Cisplatin—germ cell cancer	0.000532	0.00312	CcSEcCtD
Dabrafenib—Infestation NOS—Ifosfamide—germ cell cancer	0.000532	0.00312	CcSEcCtD
Dabrafenib—Infestation—Ifosfamide—germ cell cancer	0.000532	0.00312	CcSEcCtD
Dabrafenib—SLCO1B1—endocrine gland—germ cell cancer	0.000526	0.00448	CbGeAlD
Dabrafenib—Renal failure—Ifosfamide—germ cell cancer	0.000523	0.00306	CcSEcCtD
Dabrafenib—Stomatitis—Ifosfamide—germ cell cancer	0.000519	0.00304	CcSEcCtD
Dabrafenib—Leukopenia—Vinblastine—germ cell cancer	0.000516	0.00302	CcSEcCtD
Dabrafenib—Haematuria—Ifosfamide—germ cell cancer	0.000507	0.00297	CcSEcCtD
Dabrafenib—Pancreatitis—Cisplatin—germ cell cancer	0.000504	0.00295	CcSEcCtD
Dabrafenib—RAF1—brain—germ cell cancer	0.000503	0.00428	CbGeAlD
Dabrafenib—Chills—Bleomycin—germ cell cancer	0.000501	0.00294	CcSEcCtD
Dabrafenib—Bone disorder—Methotrexate—germ cell cancer	0.000498	0.00292	CcSEcCtD
Dabrafenib—Hypertension—Vinblastine—germ cell cancer	0.000497	0.00291	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Methotrexate—germ cell cancer	0.000495	0.0029	CcSEcCtD
Dabrafenib—Alopecia—Bleomycin—germ cell cancer	0.000494	0.00289	CcSEcCtD
Dabrafenib—Abdominal discomfort—Cisplatin—germ cell cancer	0.000493	0.00289	CcSEcCtD
Dabrafenib—SLC22A6—brain—germ cell cancer	0.000488	0.00416	CbGeAlD
Dabrafenib—Erythema—Bleomycin—germ cell cancer	0.000486	0.00285	CcSEcCtD
Dabrafenib—RAF1—lymph node—germ cell cancer	0.000486	0.00414	CbGeAlD
Dabrafenib—Alanine aminotransferase increased—Etoposide—germ cell cancer	0.000481	0.00282	CcSEcCtD
Dabrafenib—Haemoglobin—Ifosfamide—germ cell cancer	0.00048	0.00281	CcSEcCtD
Dabrafenib—Haemorrhage—Ifosfamide—germ cell cancer	0.000478	0.0028	CcSEcCtD
Dabrafenib—Urinary tract disorder—Ifosfamide—germ cell cancer	0.000472	0.00276	CcSEcCtD
Dabrafenib—Connective tissue disorder—Ifosfamide—germ cell cancer	0.000469	0.00275	CcSEcCtD
Dabrafenib—ABCB1—blood vessel—germ cell cancer	0.000468	0.00399	CbGeAlD
Dabrafenib—Urethral disorder—Ifosfamide—germ cell cancer	0.000468	0.00274	CcSEcCtD
Dabrafenib—Chills—Dactinomycin—germ cell cancer	0.000468	0.00274	CcSEcCtD
Dabrafenib—ABCG2—telencephalon—germ cell cancer	0.000461	0.00392	CbGeAlD
Dabrafenib—Alopecia—Dactinomycin—germ cell cancer	0.000461	0.0027	CcSEcCtD
Dabrafenib—Thrombocytopenia—Vinblastine—germ cell cancer	0.00046	0.0027	CcSEcCtD
Dabrafenib—Erythema—Dactinomycin—germ cell cancer	0.000454	0.00266	CcSEcCtD
Dabrafenib—Renal failure—Cisplatin—germ cell cancer	0.000451	0.00264	CcSEcCtD
Dabrafenib—Anaemia—Bleomycin—germ cell cancer	0.00045	0.00263	CcSEcCtD
Dabrafenib—Stomatitis—Cisplatin—germ cell cancer	0.000447	0.00262	CcSEcCtD
Dabrafenib—Eye disorder—Ifosfamide—germ cell cancer	0.000446	0.00261	CcSEcCtD
Dabrafenib—Neutropenia—Etoposide—germ cell cancer	0.000441	0.00258	CcSEcCtD
Dabrafenib—ABCG2—decidua—germ cell cancer	0.000437	0.00372	CbGeAlD
Dabrafenib—Leukopenia—Bleomycin—germ cell cancer	0.000435	0.00255	CcSEcCtD
Dabrafenib—Angiopathy—Ifosfamide—germ cell cancer	0.000433	0.00254	CcSEcCtD
Dabrafenib—Immune system disorder—Ifosfamide—germ cell cancer	0.000431	0.00253	CcSEcCtD
Dabrafenib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.00043	0.00252	CcSEcCtD
Dabrafenib—Chills—Ifosfamide—germ cell cancer	0.000428	0.00251	CcSEcCtD
Dabrafenib—Arrhythmia—Ifosfamide—germ cell cancer	0.000427	0.0025	CcSEcCtD
Dabrafenib—Cough—Bleomycin—germ cell cancer	0.000424	0.00249	CcSEcCtD
Dabrafenib—Alopecia—Ifosfamide—germ cell cancer	0.000422	0.00247	CcSEcCtD
Dabrafenib—Infestation NOS—Etoposide—germ cell cancer	0.00042	0.00246	CcSEcCtD
Dabrafenib—Infestation—Etoposide—germ cell cancer	0.00042	0.00246	CcSEcCtD
Dabrafenib—Anaemia—Dactinomycin—germ cell cancer	0.000419	0.00246	CcSEcCtD
Dabrafenib—Mental disorder—Ifosfamide—germ cell cancer	0.000418	0.00245	CcSEcCtD
Dabrafenib—Malnutrition—Ifosfamide—germ cell cancer	0.000416	0.00244	CcSEcCtD
Dabrafenib—Erythema—Ifosfamide—germ cell cancer	0.000416	0.00244	CcSEcCtD
Dabrafenib—Myalgia—Bleomycin—germ cell cancer	0.000414	0.00243	CcSEcCtD
Dabrafenib—Renal failure—Etoposide—germ cell cancer	0.000413	0.00242	CcSEcCtD
Dabrafenib—Stomatitis—Etoposide—germ cell cancer	0.00041	0.0024	CcSEcCtD
Dabrafenib—Decreased appetite—Vinblastine—germ cell cancer	0.000409	0.00239	CcSEcCtD
Dabrafenib—Neoplasm—Methotrexate—germ cell cancer	0.000407	0.00238	CcSEcCtD
Dabrafenib—Urinary tract disorder—Cisplatin—germ cell cancer	0.000407	0.00238	CcSEcCtD
Dabrafenib—Leukopenia—Dactinomycin—germ cell cancer	0.000406	0.00238	CcSEcCtD
Dabrafenib—Connective tissue disorder—Cisplatin—germ cell cancer	0.000405	0.00237	CcSEcCtD
Dabrafenib—Urethral disorder—Cisplatin—germ cell cancer	0.000404	0.00236	CcSEcCtD
Dabrafenib—SLC22A8—head—germ cell cancer	0.000403	0.00343	CbGeAlD
Dabrafenib—Constipation—Vinblastine—germ cell cancer	0.000402	0.00235	CcSEcCtD
Dabrafenib—Oedema—Bleomycin—germ cell cancer	0.000397	0.00233	CcSEcCtD
Dabrafenib—Infection—Bleomycin—germ cell cancer	0.000394	0.00231	CcSEcCtD
Dabrafenib—Vision blurred—Ifosfamide—germ cell cancer	0.000392	0.0023	CcSEcCtD
Dabrafenib—Thrombocytopenia—Bleomycin—germ cell cancer	0.000389	0.00228	CcSEcCtD
Dabrafenib—Myalgia—Dactinomycin—germ cell cancer	0.000386	0.00226	CcSEcCtD
Dabrafenib—CYP2C8—pituitary gland—germ cell cancer	0.000386	0.00329	CbGeAlD
Dabrafenib—Eye disorder—Cisplatin—germ cell cancer	0.000385	0.00225	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vinblastine—germ cell cancer	0.000384	0.00225	CcSEcCtD
Dabrafenib—Anaemia—Ifosfamide—germ cell cancer	0.000384	0.00225	CcSEcCtD
Dabrafenib—ABCG2—uterus—germ cell cancer	0.000382	0.00325	CbGeAlD
Dabrafenib—ABCG2—pituitary gland—germ cell cancer	0.000375	0.0032	CbGeAlD
Dabrafenib—Urinary tract disorder—Etoposide—germ cell cancer	0.000372	0.00218	CcSEcCtD
Dabrafenib—Leukopenia—Ifosfamide—germ cell cancer	0.000372	0.00218	CcSEcCtD
Dabrafenib—Immune system disorder—Cisplatin—germ cell cancer	0.000372	0.00218	CcSEcCtD
Dabrafenib—Abdominal pain—Vinblastine—germ cell cancer	0.000372	0.00218	CcSEcCtD
Dabrafenib—Mediastinal disorder—Cisplatin—germ cell cancer	0.000371	0.00217	CcSEcCtD
Dabrafenib—Hypotension—Bleomycin—germ cell cancer	0.000371	0.00217	CcSEcCtD
Dabrafenib—Oedema—Dactinomycin—germ cell cancer	0.00037	0.00217	CcSEcCtD
Dabrafenib—Urethral disorder—Etoposide—germ cell cancer	0.00037	0.00217	CcSEcCtD
Dabrafenib—Infection—Dactinomycin—germ cell cancer	0.000368	0.00215	CcSEcCtD
Dabrafenib—Arrhythmia—Cisplatin—germ cell cancer	0.000368	0.00215	CcSEcCtD
Dabrafenib—Alopecia—Cisplatin—germ cell cancer	0.000364	0.00213	CcSEcCtD
Dabrafenib—Cough—Ifosfamide—germ cell cancer	0.000363	0.00213	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000363	0.00212	CcSEcCtD
Dabrafenib—ABCG2—medulla oblongata—germ cell cancer	0.000362	0.00308	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000362	0.00212	CcSEcCtD
Dabrafenib—Hypertension—Ifosfamide—germ cell cancer	0.000359	0.0021	CcSEcCtD
Dabrafenib—Malnutrition—Cisplatin—germ cell cancer	0.000358	0.0021	CcSEcCtD
Dabrafenib—Erythema—Cisplatin—germ cell cancer	0.000358	0.0021	CcSEcCtD
Dabrafenib—Myalgia—Ifosfamide—germ cell cancer	0.000354	0.00207	CcSEcCtD
Dabrafenib—Arthralgia—Ifosfamide—germ cell cancer	0.000354	0.00207	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—germ cell cancer	0.000354	0.00207	CcSEcCtD
Dabrafenib—Eye disorder—Etoposide—germ cell cancer	0.000352	0.00206	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000351	0.00206	CcSEcCtD
Dabrafenib—Hypersensitivity—Vinblastine—germ cell cancer	0.000346	0.00203	CcSEcCtD
Dabrafenib—Decreased appetite—Bleomycin—germ cell cancer	0.000345	0.00202	CcSEcCtD
Dabrafenib—Muscle spasms—Cisplatin—germ cell cancer	0.000345	0.00202	CcSEcCtD
Dabrafenib—Angiopathy—Etoposide—germ cell cancer	0.000342	0.002	CcSEcCtD
Dabrafenib—Immune system disorder—Etoposide—germ cell cancer	0.000341	0.002	CcSEcCtD
Dabrafenib—Mediastinal disorder—Etoposide—germ cell cancer	0.00034	0.00199	CcSEcCtD
Dabrafenib—Oedema—Ifosfamide—germ cell cancer	0.000339	0.00199	CcSEcCtD
Dabrafenib—Chills—Etoposide—germ cell cancer	0.000338	0.00198	CcSEcCtD
Dabrafenib—Vision blurred—Cisplatin—germ cell cancer	0.000338	0.00198	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000337	0.00198	CcSEcCtD
Dabrafenib—Asthenia—Vinblastine—germ cell cancer	0.000337	0.00198	CcSEcCtD
Dabrafenib—Infection—Ifosfamide—germ cell cancer	0.000337	0.00197	CcSEcCtD
Dabrafenib—ABCG2—adrenal gland—germ cell cancer	0.000335	0.00285	CbGeAlD
Dabrafenib—Alopecia—Etoposide—germ cell cancer	0.000333	0.00195	CcSEcCtD
Dabrafenib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000333	0.00195	CcSEcCtD
Dabrafenib—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000332	0.00195	CcSEcCtD
Dabrafenib—Anaemia—Cisplatin—germ cell cancer	0.000331	0.00194	CcSEcCtD
Dabrafenib—ABCG2—midbrain—germ cell cancer	0.000331	0.00282	CbGeAlD
Dabrafenib—Skin disorder—Ifosfamide—germ cell cancer	0.00033	0.00193	CcSEcCtD
Dabrafenib—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000328	0.00192	CcSEcCtD
Dabrafenib—ABCG2—bone marrow—germ cell cancer	0.000324	0.00276	CbGeAlD
Dabrafenib—ABCG2—spinal cord—germ cell cancer	0.000323	0.00275	CbGeAlD
Dabrafenib—Decreased appetite—Dactinomycin—germ cell cancer	0.000322	0.00189	CcSEcCtD
Dabrafenib—Diarrhoea—Vinblastine—germ cell cancer	0.000322	0.00188	CcSEcCtD
Dabrafenib—Leukopenia—Cisplatin—germ cell cancer	0.000321	0.00188	CcSEcCtD
Dabrafenib—Fatigue—Dactinomycin—germ cell cancer	0.000319	0.00187	CcSEcCtD
Dabrafenib—Back pain—Etoposide—germ cell cancer	0.000318	0.00186	CcSEcCtD
Dabrafenib—Hypotension—Ifosfamide—germ cell cancer	0.000317	0.00186	CcSEcCtD
Dabrafenib—Muscle spasms—Etoposide—germ cell cancer	0.000316	0.00185	CcSEcCtD
Dabrafenib—Body temperature increased—Bleomycin—germ cell cancer	0.000314	0.00184	CcSEcCtD
Dabrafenib—ABCG2—female gonad—germ cell cancer	0.000313	0.00266	CbGeAlD
Dabrafenib—Dizziness—Vinblastine—germ cell cancer	0.000311	0.00182	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000309	0.00181	CcSEcCtD
Dabrafenib—Myalgia—Cisplatin—germ cell cancer	0.000305	0.00179	CcSEcCtD
Dabrafenib—Anaemia—Etoposide—germ cell cancer	0.000303	0.00178	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000303	0.00178	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000303	0.00177	CcSEcCtD
Dabrafenib—CYP2C8—endocrine gland—germ cell cancer	0.000299	0.00255	CbGeAlD
Dabrafenib—Vomiting—Vinblastine—germ cell cancer	0.000299	0.00175	CcSEcCtD
Dabrafenib—Decreased appetite—Ifosfamide—germ cell cancer	0.000295	0.00173	CcSEcCtD
Dabrafenib—Headache—Vinblastine—germ cell cancer	0.000294	0.00173	CcSEcCtD
Dabrafenib—Leukopenia—Etoposide—germ cell cancer	0.000294	0.00172	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000293	0.00172	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—germ cell cancer	0.000293	0.00171	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—germ cell cancer	0.000293	0.00171	CcSEcCtD
Dabrafenib—Fatigue—Ifosfamide—germ cell cancer	0.000293	0.00171	CcSEcCtD
Dabrafenib—Oedema—Cisplatin—germ cell cancer	0.000292	0.00171	CcSEcCtD
Dabrafenib—Hypersensitivity—Bleomycin—germ cell cancer	0.000292	0.00171	CcSEcCtD
Dabrafenib—SLC22A8—brain—germ cell cancer	0.000292	0.00249	CbGeAlD
Dabrafenib—Infection—Cisplatin—germ cell cancer	0.000291	0.0017	CcSEcCtD
Dabrafenib—Constipation—Ifosfamide—germ cell cancer	0.00029	0.0017	CcSEcCtD
Dabrafenib—ABCB1—trigeminal ganglion—germ cell cancer	0.000289	0.00246	CbGeAlD
Dabrafenib—Nervous system disorder—Cisplatin—germ cell cancer	0.000287	0.00168	CcSEcCtD
Dabrafenib—Cough—Etoposide—germ cell cancer	0.000287	0.00168	CcSEcCtD
Dabrafenib—Thrombocytopenia—Cisplatin—germ cell cancer	0.000286	0.00168	CcSEcCtD
Dabrafenib—CYP2C8—testis—germ cell cancer	0.000285	0.00243	CbGeAlD
Dabrafenib—Asthenia—Bleomycin—germ cell cancer	0.000285	0.00167	CcSEcCtD
Dabrafenib—Skin disorder—Cisplatin—germ cell cancer	0.000284	0.00166	CcSEcCtD
Dabrafenib—Hypertension—Etoposide—germ cell cancer	0.000283	0.00166	CcSEcCtD
Dabrafenib—Hyperhidrosis—Cisplatin—germ cell cancer	0.000283	0.00166	CcSEcCtD
Dabrafenib—Pruritus—Bleomycin—germ cell cancer	0.000281	0.00165	CcSEcCtD
Dabrafenib—ABCB1—embryo—germ cell cancer	0.000279	0.00238	CbGeAlD
Dabrafenib—Nausea—Vinblastine—germ cell cancer	0.000279	0.00164	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000278	0.00163	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.000277	0.00163	CcSEcCtD
Dabrafenib—ABCG2—testis—germ cell cancer	0.000277	0.00236	CbGeAlD
Dabrafenib—Pancreatitis—Methotrexate—germ cell cancer	0.000277	0.00162	CcSEcCtD
Dabrafenib—Hypotension—Cisplatin—germ cell cancer	0.000273	0.0016	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—germ cell cancer	0.000273	0.0016	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—germ cell cancer	0.000271	0.00159	CcSEcCtD
Dabrafenib—Abdominal pain—Ifosfamide—germ cell cancer	0.000268	0.00157	CcSEcCtD
Dabrafenib—Body temperature increased—Ifosfamide—germ cell cancer	0.000268	0.00157	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.000266	0.00156	CcSEcCtD
Dabrafenib—Infection—Etoposide—germ cell cancer	0.000266	0.00156	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—germ cell cancer	0.000266	0.00156	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—germ cell cancer	0.000264	0.00155	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—germ cell cancer	0.000262	0.00154	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—germ cell cancer	0.00026	0.00152	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—germ cell cancer	0.000259	0.00152	CcSEcCtD
Dabrafenib—ABCG2—cerebellum—germ cell cancer	0.000256	0.00218	CbGeAlD
Dabrafenib—Decreased appetite—Cisplatin—germ cell cancer	0.000254	0.00149	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—germ cell cancer	0.000253	0.00148	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000253	0.00148	CcSEcCtD
Dabrafenib—Vomiting—Bleomycin—germ cell cancer	0.000252	0.00148	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—germ cell cancer	0.000252	0.00147	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—germ cell cancer	0.000252	0.00147	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—germ cell cancer	0.00025	0.00147	CcSEcCtD
Dabrafenib—Rash—Bleomycin—germ cell cancer	0.00025	0.00147	CcSEcCtD
Dabrafenib—Dermatitis—Bleomycin—germ cell cancer	0.00025	0.00146	CcSEcCtD
Dabrafenib—Hypersensitivity—Ifosfamide—germ cell cancer	0.00025	0.00146	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—germ cell cancer	0.000247	0.00145	CcSEcCtD
Dabrafenib—ABCB1—retina—germ cell cancer	0.000247	0.0021	CbGeAlD
Dabrafenib—Stomatitis—Methotrexate—germ cell cancer	0.000245	0.00144	CcSEcCtD
Dabrafenib—Asthenia—Ifosfamide—germ cell cancer	0.000243	0.00143	CcSEcCtD
Dabrafenib—Pruritus—Ifosfamide—germ cell cancer	0.00024	0.00141	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—germ cell cancer	0.00024	0.00141	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—germ cell cancer	0.000237	0.00139	CcSEcCtD
Dabrafenib—Nausea—Bleomycin—germ cell cancer	0.000236	0.00138	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—germ cell cancer	0.000235	0.00138	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—germ cell cancer	0.000233	0.00137	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—germ cell cancer	0.000233	0.00136	CcSEcCtD
Dabrafenib—Diarrhoea—Ifosfamide—germ cell cancer	0.000232	0.00136	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000231	0.00136	CcSEcCtD
Dabrafenib—Body temperature increased—Cisplatin—germ cell cancer	0.000231	0.00135	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—germ cell cancer	0.000231	0.00135	CcSEcCtD
Dabrafenib—Constipation—Etoposide—germ cell cancer	0.000229	0.00134	CcSEcCtD
Dabrafenib—ABCB1—telencephalon—germ cell cancer	0.000227	0.00194	CbGeAlD
Dabrafenib—Haemoglobin—Methotrexate—germ cell cancer	0.000227	0.00133	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—germ cell cancer	0.000226	0.00132	CcSEcCtD
Dabrafenib—Dizziness—Ifosfamide—germ cell cancer	0.000224	0.00131	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—germ cell cancer	0.000223	0.00131	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—germ cell cancer	0.000221	0.0013	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—germ cell cancer	0.00022	0.00129	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—germ cell cancer	0.000219	0.00128	CcSEcCtD
Dabrafenib—Vomiting—Ifosfamide—germ cell cancer	0.000216	0.00126	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—germ cell cancer	0.000216	0.00126	CcSEcCtD
Dabrafenib—ABCB1—decidua—germ cell cancer	0.000215	0.00183	CbGeAlD
Dabrafenib—Rash—Ifosfamide—germ cell cancer	0.000214	0.00125	CcSEcCtD
Dabrafenib—CYP2C8—brain—germ cell cancer	0.000214	0.00182	CbGeAlD
Dabrafenib—Dermatitis—Ifosfamide—germ cell cancer	0.000214	0.00125	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—germ cell cancer	0.000212	0.00124	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—germ cell cancer	0.000212	0.00124	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—germ cell cancer	0.000211	0.00124	CcSEcCtD
Dabrafenib—Asthenia—Cisplatin—germ cell cancer	0.00021	0.00123	CcSEcCtD
Dabrafenib—ABCG2—brain—germ cell cancer	0.000208	0.00177	CbGeAlD
Dabrafenib—Angiopathy—Methotrexate—germ cell cancer	0.000205	0.0012	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—germ cell cancer	0.000204	0.0012	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—germ cell cancer	0.000204	0.00119	CcSEcCtD
Dabrafenib—Chills—Methotrexate—germ cell cancer	0.000203	0.00119	CcSEcCtD
Dabrafenib—CYP3A4—endocrine gland—germ cell cancer	0.000203	0.00172	CbGeAlD
Dabrafenib—Nausea—Ifosfamide—germ cell cancer	0.000202	0.00118	CcSEcCtD
Dabrafenib—ABCG2—lymph node—germ cell cancer	0.000201	0.00171	CbGeAlD
Dabrafenib—Diarrhoea—Cisplatin—germ cell cancer	0.0002	0.00117	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—germ cell cancer	0.0002	0.00117	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—germ cell cancer	0.000198	0.00116	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—germ cell cancer	0.000197	0.00116	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—germ cell cancer	0.000197	0.00115	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—germ cell cancer	0.000197	0.00115	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—germ cell cancer	0.000192	0.00113	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—germ cell cancer	0.00019	0.00111	CcSEcCtD
Dabrafenib—ABCB1—gonad—germ cell cancer	0.00019	0.00162	CbGeAlD
Dabrafenib—Pruritus—Etoposide—germ cell cancer	0.00019	0.00111	CcSEcCtD
Dabrafenib—ABCB1—uterus—germ cell cancer	0.000188	0.0016	CbGeAlD
Dabrafenib—Vomiting—Cisplatin—germ cell cancer	0.000186	0.00109	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—germ cell cancer	0.000185	0.00109	CcSEcCtD
Dabrafenib—ABCB1—pituitary gland—germ cell cancer	0.000185	0.00158	CbGeAlD
Dabrafenib—Rash—Cisplatin—germ cell cancer	0.000184	0.00108	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—germ cell cancer	0.000184	0.00108	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—germ cell cancer	0.000183	0.00107	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—germ cell cancer	0.000182	0.00106	CcSEcCtD
Dabrafenib—ABCB1—medulla oblongata—germ cell cancer	0.000179	0.00152	CbGeAlD
Dabrafenib—Dizziness—Etoposide—germ cell cancer	0.000177	0.00104	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—germ cell cancer	0.000176	0.00103	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—germ cell cancer	0.000174	0.00102	CcSEcCtD
Dabrafenib—Cough—Methotrexate—germ cell cancer	0.000172	0.00101	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—germ cell cancer	0.00017	0.000998	CcSEcCtD
Dabrafenib—Rash—Etoposide—germ cell cancer	0.000169	0.00099	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—germ cell cancer	0.000169	0.000989	CcSEcCtD
Dabrafenib—Headache—Etoposide—germ cell cancer	0.000168	0.000983	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—germ cell cancer	0.000167	0.000981	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—germ cell cancer	0.000167	0.000981	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.000166	0.000974	CcSEcCtD
Dabrafenib—ABCB1—adrenal gland—germ cell cancer	0.000165	0.00141	CbGeAlD
Dabrafenib—ABCB1—midbrain—germ cell cancer	0.000163	0.00139	CbGeAlD
Dabrafenib—ABCB1—bone marrow—germ cell cancer	0.00016	0.00136	CbGeAlD
Dabrafenib—Infection—Methotrexate—germ cell cancer	0.000159	0.000934	CcSEcCtD
Dabrafenib—ABCB1—spinal cord—germ cell cancer	0.000159	0.00136	CbGeAlD
Dabrafenib—Nausea—Etoposide—germ cell cancer	0.000159	0.000932	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—germ cell cancer	0.000157	0.000922	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—germ cell cancer	0.000157	0.000921	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—germ cell cancer	0.000156	0.000913	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—germ cell cancer	0.000155	0.000909	CcSEcCtD
Dabrafenib—ABCB1—female gonad—germ cell cancer	0.000154	0.00131	CbGeAlD
Dabrafenib—RAF1—Signaling by SCF-KIT—FGFR3—germ cell cancer	0.000152	0.00147	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—AVP—germ cell cancer	0.000152	0.00147	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—CD9—germ cell cancer	0.000151	0.00146	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KITLG—germ cell cancer	0.000151	0.00146	CbGpPWpGaD
Dabrafenib—Hypotension—Methotrexate—germ cell cancer	0.00015	0.000879	CcSEcCtD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—MYC—germ cell cancer	0.00015	0.00144	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	0.000149	0.00144	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	0.000148	0.00143	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	0.000146	0.000857	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—FGFR3—germ cell cancer	0.000145	0.0014	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR3—germ cell cancer	0.000145	0.0014	CbGpPWpGaD
Dabrafenib—Insomnia—Methotrexate—germ cell cancer	0.000145	0.00085	CcSEcCtD
Dabrafenib—RAF1—Interleukin-2 signaling—HRAS—germ cell cancer	0.000145	0.0014	CbGpPWpGaD
Dabrafenib—ABCB1—endocrine gland—germ cell cancer	0.000143	0.00122	CbGeAlD
Dabrafenib—RAF1—Signaling by ERBB4—FGFR3—germ cell cancer	0.000143	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—germ cell cancer	0.000143	0.00138	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—FGFR3—germ cell cancer	0.000142	0.00137	CbGpPWpGaD
Dabrafenib—ABCB1—head—germ cell cancer	0.000142	0.0012	CbGeAlD
Dabrafenib—RAF1—Signaling by NGF—FGF4—germ cell cancer	0.000141	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—MYC—germ cell cancer	0.000141	0.00136	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—TP53—germ cell cancer	0.000141	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—IL-3 Signaling Pathway—HRAS—germ cell cancer	0.00014	0.00136	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	0.00014	0.00135	CbGpPWpGaD
Dabrafenib—Decreased appetite—Methotrexate—germ cell cancer	0.00014	0.000817	CcSEcCtD
Dabrafenib—RAF1—Signaling by SCF-KIT—KIT—germ cell cancer	0.000139	0.00135	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Methotrexate—germ cell cancer	0.000139	0.000812	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—germ cell cancer	0.000138	0.000811	CcSEcCtD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	0.000138	0.00133	CbGpPWpGaD
Dabrafenib—ABCB1—testis—germ cell cancer	0.000137	0.00116	CbGeAlD
Dabrafenib—RAF1—Downstream signal transduction—FGFR3—germ cell cancer	0.000137	0.00132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—germ cell cancer	0.000136	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FGFR3—germ cell cancer	0.000136	0.00131	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGF4—germ cell cancer	0.000136	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—FGFR3—germ cell cancer	0.000135	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	0.000135	0.0013	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FGFR3—germ cell cancer	0.000135	0.0013	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—HRAS—germ cell cancer	0.000134	0.0013	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—KIT—germ cell cancer	0.000133	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	0.000133	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—KIT—germ cell cancer	0.000131	0.00127	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Methotrexate—germ cell cancer	0.000131	0.000769	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—KIT—germ cell cancer	0.000131	0.00126	CbGpPWpGaD
Dabrafenib—RAF1—IL2-mediated signaling events—HRAS—germ cell cancer	0.00013	0.00125	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	0.000127	0.00123	CbGpPWpGaD
Dabrafenib—Body temperature increased—Methotrexate—germ cell cancer	0.000127	0.000743	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—germ cell cancer	0.000127	0.000743	CcSEcCtD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—AVP—germ cell cancer	0.000127	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGFR3—germ cell cancer	0.000127	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGFR3—germ cell cancer	0.000127	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—germ cell cancer	0.000127	0.00122	CbGpPWpGaD
Dabrafenib—ABCB1—cerebellum—germ cell cancer	0.000126	0.00108	CbGeAlD
Dabrafenib—RAF1—Signaling by EGFR—FGFR3—germ cell cancer	0.000125	0.00121	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—KIT—germ cell cancer	0.000125	0.00121	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	0.000125	0.00121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—KIT—germ cell cancer	0.000125	0.00121	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGFR3—germ cell cancer	0.000125	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—germ cell cancer	0.000124	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SOX2—germ cell cancer	0.000124	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—KIT—germ cell cancer	0.000124	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGFR3—germ cell cancer	0.000124	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—KIT—germ cell cancer	0.000124	0.00119	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—HRAS—germ cell cancer	0.000123	0.00118	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PVRL2—germ cell cancer	0.000122	0.00118	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—MYC—germ cell cancer	0.000122	0.00118	CbGpPWpGaD
Dabrafenib—RAF1—Kit receptor signaling pathway—HRAS—germ cell cancer	0.000121	0.00117	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Methotrexate—germ cell cancer	0.000118	0.000693	CcSEcCtD
Dabrafenib—RAF1—Fc-epsilon receptor I signaling in mast cells—HRAS—germ cell cancer	0.000118	0.00114	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	0.000118	0.00114	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—HRAS—germ cell cancer	0.000117	0.00113	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—TP53—germ cell cancer	0.000117	0.00113	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—germ cell cancer	0.000116	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KIT—germ cell cancer	0.000116	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—KIT—germ cell cancer	0.000116	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KITLG—germ cell cancer	0.000116	0.00112	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	0.000116	0.00112	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—AVP—germ cell cancer	0.000115	0.00111	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—germ cell cancer	0.000115	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KIT—germ cell cancer	0.000115	0.00111	CbGpPWpGaD
Dabrafenib—Asthenia—Methotrexate—germ cell cancer	0.000115	0.000675	CcSEcCtD
Dabrafenib—RAF1—Endothelins—HRAS—germ cell cancer	0.000115	0.00111	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—HRAS—germ cell cancer	0.000115	0.00111	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KIT—germ cell cancer	0.000114	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KIT—germ cell cancer	0.000114	0.0011	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KIT—germ cell cancer	0.000114	0.0011	CbGpPWpGaD
Dabrafenib—Pruritus—Methotrexate—germ cell cancer	0.000114	0.000665	CcSEcCtD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—MYC—germ cell cancer	0.000113	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—germ cell cancer	0.000112	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—HRAS—germ cell cancer	0.000112	0.00108	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KITLG—germ cell cancer	0.000111	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—mTOR signaling pathway—HRAS—germ cell cancer	0.000111	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—HRAS—germ cell cancer	0.000111	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—HRAS—germ cell cancer	0.000111	0.00107	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—HRAS—germ cell cancer	0.00011	0.00106	CbGpPWpGaD
Dabrafenib—BRAF—ErbB1 downstream signaling—HRAS—germ cell cancer	0.00011	0.00106	CbGpPWpGaD
Dabrafenib—Diarrhoea—Methotrexate—germ cell cancer	0.00011	0.000643	CcSEcCtD
Dabrafenib—RAF1—BCR signaling pathway—HRAS—germ cell cancer	0.000109	0.00106	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SLC2A3—germ cell cancer	0.000109	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—NCAM signaling for neurite out-growth—HRAS—germ cell cancer	0.000108	0.00104	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	0.000107	0.00104	CbGpPWpGaD
Dabrafenib—Dizziness—Methotrexate—germ cell cancer	0.000106	0.000622	CcSEcCtD
Dabrafenib—RAF1—CDC42 signaling events—HRAS—germ cell cancer	0.000106	0.00102	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—MYC—germ cell cancer	0.000105	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—MYC—germ cell cancer	0.000103	0.001	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—germ cell cancer	0.000103	0.000994	CbGpPWpGaD
Dabrafenib—ABCB1—brain—germ cell cancer	0.000103	0.000873	CbGeAlD
Dabrafenib—Vomiting—Methotrexate—germ cell cancer	0.000102	0.000598	CcSEcCtD
Dabrafenib—Rash—Methotrexate—germ cell cancer	0.000101	0.000593	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—germ cell cancer	0.000101	0.000592	CcSEcCtD
Dabrafenib—Headache—Methotrexate—germ cell cancer	0.000101	0.000589	CcSEcCtD
Dabrafenib—RAF1—Leptin signaling pathway—HRAS—germ cell cancer	9.99e-05	0.000964	CbGpPWpGaD
Dabrafenib—ABCB1—lymph node—germ cell cancer	9.91e-05	0.000844	CbGeAlD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SCNN1A—germ cell cancer	9.72e-05	0.000939	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—germ cell cancer	9.72e-05	0.000939	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—MYC—germ cell cancer	9.64e-05	0.000931	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—HRAS—germ cell cancer	9.59e-05	0.000926	CbGpPWpGaD
Dabrafenib—Nausea—Methotrexate—germ cell cancer	9.53e-05	0.000559	CcSEcCtD
Dabrafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—germ cell cancer	9.48e-05	0.000916	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—HRAS—germ cell cancer	9.3e-05	0.000898	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—germ cell cancer	9.27e-05	0.000896	CbGpPWpGaD
Dabrafenib—RAF1—IRS-mediated signalling—HRAS—germ cell cancer	9.03e-05	0.000873	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—HRAS—germ cell cancer	8.95e-05	0.000865	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC2A3—germ cell cancer	8.86e-05	0.000855	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events—HRAS—germ cell cancer	8.79e-05	0.000849	CbGpPWpGaD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—germ cell cancer	8.76e-05	0.000846	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC22A3—germ cell cancer	8.72e-05	0.000843	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—AVP—germ cell cancer	8.72e-05	0.000842	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—HRAS—germ cell cancer	8.71e-05	0.000841	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—HRAS—germ cell cancer	8.63e-05	0.000834	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGFR3—germ cell cancer	8.63e-05	0.000833	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—germ cell cancer	8.62e-05	0.000833	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—HRAS—germ cell cancer	8.48e-05	0.000819	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—HRAS—germ cell cancer	8.48e-05	0.000819	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—HRAS—germ cell cancer	8.48e-05	0.000819	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—MYC—germ cell cancer	8.45e-05	0.000816	CbGpPWpGaD
Dabrafenib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—germ cell cancer	8.43e-05	0.000814	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGFR3—germ cell cancer	8.28e-05	0.0008	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—HRAS—germ cell cancer	8.13e-05	0.000785	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—MYC—germ cell cancer	8.09e-05	0.000781	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF4—germ cell cancer	8.06e-05	0.000778	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—germ cell cancer	7.98e-05	0.00077	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—HRAS—germ cell cancer	7.93e-05	0.000766	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KIT—germ cell cancer	7.92e-05	0.000765	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—germ cell cancer	7.92e-05	0.000765	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—HRAS—germ cell cancer	7.79e-05	0.000753	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	7.79e-05	0.000753	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF4—germ cell cancer	7.74e-05	0.000747	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—AVP—germ cell cancer	7.72e-05	0.000745	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—HRAS—germ cell cancer	7.63e-05	0.000737	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—HRAS—germ cell cancer	7.63e-05	0.000737	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KIT—germ cell cancer	7.61e-05	0.000735	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SLC2A3—germ cell cancer	7.54e-05	0.000729	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—HRAS—germ cell cancer	7.51e-05	0.000726	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—HRAS—germ cell cancer	7.46e-05	0.00072	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PVRL2—germ cell cancer	7.43e-05	0.000717	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—HRAS—germ cell cancer	7.26e-05	0.000701	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CRABP1—germ cell cancer	7.11e-05	0.000687	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—HRAS—germ cell cancer	7.09e-05	0.000685	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—HRAS—germ cell cancer	7.04e-05	0.00068	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—HRAS—germ cell cancer	6.86e-05	0.000663	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—MYC—germ cell cancer	6.67e-05	0.000644	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—germ cell cancer	6.64e-05	0.000642	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—HRAS—germ cell cancer	6.64e-05	0.000641	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KITLG—germ cell cancer	6.62e-05	0.000639	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—HRAS—germ cell cancer	6.59e-05	0.000636	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—AVP—germ cell cancer	6.44e-05	0.000622	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	6.43e-05	0.000621	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—HRAS—germ cell cancer	6.39e-05	0.000617	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC2A3—germ cell cancer	6.36e-05	0.000614	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KITLG—germ cell cancer	6.36e-05	0.000614	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC22A3—germ cell cancer	6.27e-05	0.000605	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF4—germ cell cancer	6.26e-05	0.000605	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—AVP—germ cell cancer	6.22e-05	0.000601	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	6.17e-05	0.000596	CbGpPWpGaD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—germ cell cancer	6.06e-05	0.000585	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—HRAS—germ cell cancer	6.03e-05	0.000582	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	6.02e-05	0.000581	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—OXT—germ cell cancer	6.02e-05	0.000581	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC2A3—germ cell cancer	5.95e-05	0.000575	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—HRAS—germ cell cancer	5.93e-05	0.000572	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC22A3—germ cell cancer	5.86e-05	0.000566	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—AVP—germ cell cancer	5.86e-05	0.000566	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—HRAS—germ cell cancer	5.77e-05	0.000557	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—HRAS—germ cell cancer	5.67e-05	0.000548	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HRAS—germ cell cancer	5.64e-05	0.000545	CbGpPWpGaD
Dabrafenib—BRAF—Disease—H2AFZ—germ cell cancer	5.59e-05	0.00054	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC2A3—germ cell cancer	5.51e-05	0.000532	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—germ cell cancer	5.48e-05	0.000529	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—HRAS—germ cell cancer	5.45e-05	0.000526	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC22A3—germ cell cancer	5.43e-05	0.000524	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—AVP—germ cell cancer	5.43e-05	0.000524	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—HRAS—germ cell cancer	5.42e-05	0.000523	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	5.39e-05	0.000521	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—HRAS—germ cell cancer	5.39e-05	0.000521	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—HRAS—germ cell cancer	5.37e-05	0.000518	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—HRAS—germ cell cancer	5.34e-05	0.000516	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KITLG—germ cell cancer	5.14e-05	0.000497	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—OXT—germ cell cancer	5.14e-05	0.000496	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—HRAS—germ cell cancer	5.05e-05	0.000487	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—HRAS—germ cell cancer	5.02e-05	0.000485	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	5.02e-05	0.000485	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HRAS—germ cell cancer	5.02e-05	0.000485	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—HRAS—germ cell cancer	4.98e-05	0.000481	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—HRAS—germ cell cancer	4.95e-05	0.000478	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	4.94e-05	0.000477	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—HRAS—germ cell cancer	4.93e-05	0.000477	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGFR3—germ cell cancer	4.92e-05	0.000475	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—HRAS—germ cell cancer	4.91e-05	0.000475	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CRABP1—germ cell cancer	4.78e-05	0.000462	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—HRAS—germ cell cancer	4.75e-05	0.000458	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR3—germ cell cancer	4.72e-05	0.000456	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF4—germ cell cancer	4.69e-05	0.000453	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—HRAS—germ cell cancer	4.56e-05	0.00044	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KIT—germ cell cancer	4.52e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	4.45e-05	0.00043	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CRABP1—germ cell cancer	4.42e-05	0.000427	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF4—germ cell cancer	4.39e-05	0.000424	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KIT—germ cell cancer	4.34e-05	0.000419	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF4—germ cell cancer	4.33e-05	0.000418	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—germ cell cancer	4.3e-05	0.000415	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AVP—germ cell cancer	4.12e-05	0.000398	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—H2AFZ—germ cell cancer	3.92e-05	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—Disease—H2AFZ—germ cell cancer	3.87e-05	0.000374	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KITLG—germ cell cancer	3.86e-05	0.000372	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR3—germ cell cancer	3.82e-05	0.000369	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KITLG—germ cell cancer	3.6e-05	0.000348	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KITLG—germ cell cancer	3.56e-05	0.000344	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—OXT—germ cell cancer	3.55e-05	0.000343	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AVP—germ cell cancer	3.52e-05	0.00034	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KIT—germ cell cancer	3.51e-05	0.000339	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—germ cell cancer	3.49e-05	0.000337	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—germ cell cancer	3.48e-05	0.000336	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—germ cell cancer	3.42e-05	0.000331	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A3—germ cell cancer	3.42e-05	0.00033	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC22A3—germ cell cancer	3.37e-05	0.000325	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—germ cell cancer	3.29e-05	0.000317	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—germ cell cancer	3.1e-05	0.000299	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF4—germ cell cancer	3.03e-05	0.000293	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A3—germ cell cancer	2.98e-05	0.000288	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC22A3—germ cell cancer	2.93e-05	0.000283	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	2.93e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR3—germ cell cancer	2.87e-05	0.000277	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	2.84e-05	0.000274	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CRABP1—germ cell cancer	2.75e-05	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—H2AFZ—germ cell cancer	2.71e-05	0.000262	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR3—germ cell cancer	2.68e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR3—germ cell cancer	2.65e-05	0.000256	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—germ cell cancer	2.63e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KITLG—germ cell cancer	2.49e-05	0.000241	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—germ cell cancer	2.46e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AVP—germ cell cancer	2.44e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—germ cell cancer	2.43e-05	0.000235	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CRABP1—germ cell cancer	2.39e-05	0.000231	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	2.33e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—germ cell cancer	2.27e-05	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—germ cell cancer	2.21e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—germ cell cancer	2.17e-05	0.000209	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—germ cell cancer	1.95e-05	0.000189	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—germ cell cancer	1.93e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—germ cell cancer	1.87e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—germ cell cancer	1.85e-05	0.000179	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	1.84e-05	0.000177	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	1.81e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—germ cell cancer	1.7e-05	0.000164	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—germ cell cancer	1.52e-05	0.000147	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CRABP1—germ cell cancer	1.47e-05	0.000142	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—germ cell cancer	1.35e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—germ cell cancer	1.34e-05	0.000129	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—germ cell cancer	1.24e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—germ cell cancer	1.14e-05	0.00011	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—germ cell cancer	1.11e-05	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—germ cell cancer	1.06e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—germ cell cancer	1.05e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—germ cell cancer	9.36e-06	9.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—germ cell cancer	7.69e-06	7.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—germ cell cancer	7.35e-06	7.1e-05	CbGpPWpGaD
